Oligopeptide-68

What is Oligopeptide-68?

Oligopeptide-68 is a synthetic ten-amino-acid peptide with the sequence Arg-Asp-Gly-Gln-Ile-Leu-Ser-Thr-Trp-Tyr (CAS 1206525-47-4). It is the active ingredient in β-WHITE™, the branded cosmetic ingredient developed by Lucas Meyer Cosmetics (now part of IFF) for skin-brightening and hyperpigmentation applications. Unlike tyrosinase inhibitors (hydroquinone, kojic acid, decapeptide-12) that block the enzyme catalyzing melanin synthesis, Oligopeptide-68 is positioned as a signal peptide that interferes with MITF (microphthalmia-associated transcription factor), the master transcriptional regulator of melanocyte differentiation and pigmentation. By downregulating MITF, it is proposed to secondarily reduce expression of tyrosinase, TRP-1, and TRP-2 — suppressing melanogenesis at the transcriptional level rather than the enzymatic level. Typical formulated concentrations are 1.0–2.5%. Most of the published efficacy evidence is manufacturer-sponsored; independent clinical replication is limited.

What Oligopeptide-68 Is Investigated For

Oligopeptide-68 is investigated as a topical cosmetic peptide for melasma, hyperpigmentation, and general skin brightening. Its proposed mechanism is distinctive among pigmentation-targeting ingredients: rather than directly inhibiting tyrosinase (the approach of hydroquinone, kojic acid, arbutin, and decapeptide-12), it acts upstream at the transcriptional level by suppressing MITF and consequently reducing the expression of tyrosinase, TRP-1, and TRP-2. In principle, this transcriptional approach should produce a more durable and compartment-specific effect than enzymatic inhibition, and it sidesteps some of the tolerability issues associated with hydroquinone at higher concentrations. The honest caveats are significant: the efficacy and tolerability data cited in marketing materials is primarily manufacturer-sponsored, independent peer-reviewed clinical replication is limited, and head-to-head trials against better-established depigmenting agents are scarce. It is best understood as a mechanistically interesting cosmetic ingredient with a compelling theoretical story and thin independent clinical evidence rather than a validated therapeutic for pigmentary disorders.

How It Works

Oligopeptide-68 is a short synthetic peptide used in brightening serums and creams. Most skin-lightening ingredients work by blocking the enzyme that makes melanin. Oligopeptide-68 instead works one level upstream — it suppresses the 'controller' protein (MITF) that tells pigment cells how much of that enzyme to make. Less controller activity means less enzyme produced, which means less melanin over time. Whether this translates into visibly better results than established brighteners like hydroquinone hasn't been firmly established in independent clinical studies.

Oligopeptide-68 (Arg-Asp-Gly-Gln-Ile-Leu-Ser-Thr-Trp-Tyr) is proposed to act as a signal peptide that suppresses MITF (microphthalmia-associated transcription factor) expression or activity in melanocytes. MITF is the central transcriptional regulator of the melanocyte differentiation program; it drives expression of the core melanogenic enzymes tyrosinase, TRP-1 (tyrosinase-related protein 1), and TRP-2 (dopachrome tautomerase), as well as the PMEL17 structural protein that organizes melanosomes. Downregulating MITF reduces enzyme production downstream, producing a net decrease in eumelanin synthesis over time. The specific molecular target through which Oligopeptide-68 engages the MITF pathway is not clearly established in independent published work — manufacturer materials describe the effect at the transcriptional level but do not definitively resolve whether the peptide acts at a surface receptor, intracellularly, or through a secondary signaling intermediate. The effect is reported in cellular melanogenesis assays and in manufacturer-conducted clinical studies using pigmentation-measurement endpoints. The transcriptional mechanism is biologically plausible — MITF is a well-characterized master regulator and peptide-mediated transcription factor modulation is an established cosmetic-active strategy — but the receptor-level specifics remain underspecified in the public literature.

Evidence Snapshot

Forms & Administration

Topical application in serums, creams, spot treatments, and comprehensive brightening formulations. Typical in-product concentrations are 1.0–2.5% of the branded β-WHITE™ ingredient. Often layered with other brightening actives (niacinamide, tranexamic acid, vitamin C, azelaic acid) in anti-pigmentation regimens. Not for injection. Dermal bioavailability is a general challenge for decapeptide topicals — vehicle and carrier systems materially affect penetration to the melanocyte compartment.

Common Questions

Safety Profile